Comparative Pharmacology
Head-to-head clinical analysis: AIRSUPRA versus SYMBICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRSUPRA versus SYMBICORT.
AIRSUPRA vs SYMBICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AIRSUPRA is a fixed-dose combination of albuterol (a short-acting beta2-agonist) and budesonide (an inhaled corticosteroid). Albuterol relaxes bronchial smooth muscle via beta2-adrenergic receptor activation, increasing cAMP and causing bronchodilation. Budesonide reduces airway inflammation by binding to glucocorticoid receptors, modulating gene transcription to suppress inflammatory mediators.
Symbicort is a combination product containing budesonide, a corticosteroid, and formoterol fumarate dihydrate, a long-acting beta2-adrenergic agonist (LABA). Budesonide reduces inflammation by inhibiting inflammatory mediators and suppressing airway hyperresponsiveness. Formoterol stimulates beta2-adrenergic receptors in bronchial smooth muscle, leading to bronchodilation via increased cyclic AMP. The combination provides anti-inflammatory and bronchodilatory effects.
2 inhalations (albuterol 180 mcg / budesonide 160 mcg) orally inhaled twice daily (morning and evening), maximum 2 inhalations twice daily.
1-2 inhalations (80/4.5 mcg or 160/4.5 mcg) twice daily; maximum 2 inhalations twice daily of 160/4.5 mcg.
None Documented
None Documented
Budesonide: 2-3 hours; formoterol: 10-14 hours; clinical context: steady state achieved within days for both
Budesonide: 2–3 hours (terminal); Formoterol: 10 hours (terminal). Clinical context: Twice-daily dosing maintains bronchodilation.
Budesonide: ~60% renal as metabolites, ~40% fecal; formoterol: ~60% renal, ~40% fecal
Budesonide: 60% renal (as metabolites), 40% fecal; Formoterol: 60% renal (as metabolites), 40% fecal.
Category C
Category C
Inhaled Corticosteroid/SABA Combination
Inhaled Corticosteroid/Long-Acting Beta Agonist